345 related articles for article (PubMed ID: 19560355)
1. Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I.
Furet P; Schoepfer J; Radimerski T; Chène P
Bioorg Med Chem Lett; 2009 Aug; 19(15):4014-7. PubMed ID: 19560355
[TBL] [Abstract][Full Text] [Related]
2. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE
Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158
[TBL] [Abstract][Full Text] [Related]
5. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
6. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
Sai Krishna AD; Panda G; Kondapi AK
Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
[TBL] [Abstract][Full Text] [Related]
8. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
9. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
[TBL] [Abstract][Full Text] [Related]
10. Critical structural motif for the catalytic inhibition of human topoisomerase II by UK-1 and analogs.
Wang BB; Maghami N; Goodlin VL; Smith PJ
Bioorg Med Chem Lett; 2004 Jun; 14(12):3221-6. PubMed ID: 15149679
[TBL] [Abstract][Full Text] [Related]
11. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.
Cancilla MT; He MM; Viswanathan N; Simmons RL; Taylor M; Fung AD; Cao K; Erlanson DA
Bioorg Med Chem Lett; 2008 Jul; 18(14):3978-81. PubMed ID: 18579375
[TBL] [Abstract][Full Text] [Related]
12. A novel homogenous assay for topoisomerase II action and inhibition.
Jahnz M; Medina MA; Schwille P
Chembiochem; 2005 May; 6(5):920-6. PubMed ID: 15812853
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.
Jiménez-Alonso S; Orellana HC; Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Machín F
J Med Chem; 2008 Nov; 51(21):6761-72. PubMed ID: 18816045
[TBL] [Abstract][Full Text] [Related]
14. Rational design of novel glycomimetics: inhibitors of concanavalin A.
Welch KT; Turner TA; Preast CE
Bioorg Med Chem Lett; 2008 Dec; 18(24):6573-5. PubMed ID: 18990567
[TBL] [Abstract][Full Text] [Related]
15. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity.
Stocks MJ; Barber S; Ford R; Leroux F; St-Gallay S; Teague S; Xue Y
Bioorg Med Chem Lett; 2005 Jul; 15(14):3459-62. PubMed ID: 15950471
[TBL] [Abstract][Full Text] [Related]
16. Identification of potent, selective protein kinase C inhibitors based on a phorbol skeleton.
Yamatsugu K; Motoki R; Kanai M; Shibasaki M
Chem Asian J; 2006 Sep; 1(3):314-21. PubMed ID: 17441066
[TBL] [Abstract][Full Text] [Related]
17. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
Park H; Bahn YJ; Ryu SE
Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
[TBL] [Abstract][Full Text] [Related]
18. Structure-based virtual screening: an application to human topoisomerase II alpha.
Christmann-Franck S; Bertrand HO; Goupil-Lamy A; der Garabedian PA; Mauffret O; Hoffmann R; Fermandjian S
J Med Chem; 2004 Dec; 47(27):6840-53. PubMed ID: 15615533
[TBL] [Abstract][Full Text] [Related]
19. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
Charifson PS; Grillot AL; Grossman TH; Parsons JD; Badia M; Bellon S; Deininger DD; Drumm JE; Gross CH; LeTiran A; Liao Y; Mani N; Nicolau DP; Perola E; Ronkin S; Shannon D; Swenson LL; Tang Q; Tessier PR; Tian SK; Trudeau M; Wang T; Wei Y; Zhang H; Stamos D
J Med Chem; 2008 Sep; 51(17):5243-63. PubMed ID: 18690678
[TBL] [Abstract][Full Text] [Related]
20. Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIα.
Pogorelčnik B; Brvar M; Zajc I; Filipič M; Solmajer T; Perdih A
Bioorg Med Chem Lett; 2014 Dec; 24(24):5762-5768. PubMed ID: 25453816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
